Skip to main content
SpringerLink
Log in

Topical Treatment of Field Cancerization

  • Chapter
Skin Cancer after Organ Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 146))

The concept of “field cancerization” was established by Slaughter [1] in 1953 to describe the presence of histologically abnormal tissue surrounding an invasive squamous cell carcinoma from the upper gastrointestinal tract. The term was proposed to explain the development of multiple primary tumours and locally recurrent cancer; this specifically accounts for organ systems such as the skin (head and neck) cancers, in the ENT areas (oral cavity, oropharynx, and larynx), but also the lung, vulva, esophagus, cervix, breast, skin, colon, and bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer 1953; 6:963–8.

    Article  PubMed  CAS  Google Scholar 

  2. Hitt R, Echarri MJ. Molecular biology in head and neck cancer. Clin Transl Oncol 2006; 8:776–9.

    Article  PubMed  CAS  Google Scholar 

  3. Boyle J, MacKie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1984; 1:702–5.

    Article  PubMed  CAS  Google Scholar 

  4. Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2005; 353:2712–3.

    Article  PubMed  CAS  Google Scholar 

  5. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58:365–72.

    PubMed  CAS  Google Scholar 

  6. Hemmi H, Kaisho T, Takeuchi O et al. Small antiviral compounds activate immune cells via the TLR7MyD88-dependent signal pathway. Nat Immunol 2002; 3:196–200, 211, 212.

    Article  PubMed  CAS  Google Scholar 

  7. Lebwohl M, Dinehart S, Whiting D, Lee P, Tawfik N, Jorizzo J, Lee J, Fox T. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714–21.

    Article  PubMed  Google Scholar 

  8. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004; 140:1542.

    Article  PubMed  Google Scholar 

  9. Vidal D, Alomar A. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol 2004; 29:237–239.

    Article  PubMed  CAS  Google Scholar 

  10. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141:985–93.

    Article  PubMed  CAS  Google Scholar 

  11. Ulrich C, Hackethal M, Ulrich M, Howorka A, Forschner T, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007;Suppl 3:40–2.

    Google Scholar 

  12. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PCM, Amerio P, Rønnevig J, Slade HB, Stockfleth E. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157(Suppl 2):25–31.

    PubMed  CAS  Google Scholar 

  13. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry E, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl 2):34–40.

    PubMed  CAS  Google Scholar 

  14. Wolfe CM, Tafuri N, Hatfield K. Exacerbation of myasthenia gravis during imiquimod treatment. J Drugs Dermatol 2007; 6:745–6.

    PubMed  Google Scholar 

  15. Sidoroff A. Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review. Hautarzt 2007; 58:577–84.

    Article  PubMed  CAS  Google Scholar 

  16. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Dermatol Venereol 2006; 86:25–8.

    CAS  Google Scholar 

  17. Dragieva G, Prinz BM, Hafner J, Dummer R et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151:196–200.

    Article  PubMed  CAS  Google Scholar 

  18. de Graaf YG, Kennedy C, Wolterbeek R et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126:569–74.

    Article  PubMed  CAS  Google Scholar 

  19. Dragieva G, Hafner J, Dummer R et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation 2004; 77:1–6.

    Article  Google Scholar 

  20. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156:320–8.

    Article  PubMed  CAS  Google Scholar 

  21. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol 1970; 101:132–9.

    Article  PubMed  CAS  Google Scholar 

  22. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27:561–4.

    Article  PubMed  CAS  Google Scholar 

  23. Fisher SM. Is cyclooxygenase-2 important in skin carcinogenesis? J Environ Pathol Toxicol Oncol 2002; 21:183–91.

    Google Scholar 

  24. Buckmann SY, Gresham A, Hale P et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19:723–9.

    Article  Google Scholar 

  25. Kagoura M, Toyoda M, Masuri C, Morohashi M. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J Cutan Pathol 2001; 28:298–302.

    Article  PubMed  CAS  Google Scholar 

  26. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004; 151:837–45.

    Article  PubMed  CAS  Google Scholar 

  27. William CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589–94.

    Article  Google Scholar 

  28. Gallo O, Franchi A, Magnelli L et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for tumour angiogenesis and metastasis. Neoplasia 2001; 3:53–61.

    Article  PubMed  CAS  Google Scholar 

  29. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaniah K. Inhibition of cyclooxygenase-2: an approach to preventing cancers of the upper aerodigestive tract. Ann N Y Acad Sci 2001; 952:109–15.

    Article  PubMed  CAS  Google Scholar 

  30. Cortes R. Correspondence. Int J Dermatol 2002; 44:371–3.

    Google Scholar 

  31. Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146:94–100.

    Article  PubMed  CAS  Google Scholar 

  32. Seed MP, Brown JR, Freemantle CN et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997; 57:1625–9.

    PubMed  CAS  Google Scholar 

  33. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 1992; 24:990–1000.

    Article  Google Scholar 

  34. Ulrich C, Hackethal M, Ulrich M, Howorka A, Forschner T, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007; 156(Suppl 3):40–2.

    Article  PubMed  CAS  Google Scholar 

  35. Ulrich C, Johannsen A, Hackethal M, Ulrich M, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant patients. (in preparation).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Transplant-Aftercare Unit, Charité – Universitätsmedizin Berlin, 13353 Berlin, Germany

    Claas Ulrich

Authors
  1. Claas Ulrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Dermatologie Venerologie und Allergologie, Charité - Universitätsklinikum Berlin Charite Campus Mitte Klinik und Poliklinik for Dermatologie, Charitéplatz 1, 10117 Berlin, Germany

    Eggert Stockfleth MD, PhD  & Claas Ulrich  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ulrich, C. (2009). Topical Treatment of Field Cancerization. In: Stockfleth, E., Ulrich, C. (eds) Skin Cancer after Organ Transplantation. Cancer Treatment and Research, vol 146. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-78574-5_36

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-78574-5_36

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-78573-8

  • Online ISBN: 978-0-387-78574-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation